Practical aspects of FK 506 analysis (Pittsburgh experience) by Warty, VS et al.
i 
~II"IK"I-K--­,----- II~ 
/:5/# 
Practical Aspects of FK 506 Analysis (Pittsburgh Experience) 
v.s. Warty, R. Venkataramanan, P. Zendehrouh, S. Mehta, T. McKaveney, J. Flowers, S. Zuckerman, 
A. Krajak, A. Zeevi, J. Fung, S. Todo, and T.E. Starzl 
FK 506 is a potent immunosuppressive compound. I However, like cyclosporine (CyA) it has certain side 
effects, such as neurotoxicity and nephrotoxicity. This fact 
is very well documented in a recent paper by Abu-Elmagd 
et a\.2 In this paper, the authors have indicated that 
patients who continued to have bad liver functions after 
transplantation have high FK 506 concentrations and cor-
respondingly increased nephrotoxicity that appears to re-
main for a longer period of time in spite of receiving lower 
dosages. There is also wide variations in the pharmacoki-
netics of FK 506. This means that for a given dose of FK 
506, there is a wide variation in plasma concentrations. 
Additionally, FK 506, like CyA. exhibits a narrow thera-
peutic index. 
At the University of Pittsburgh Medical Center, we have 
been analyzing plasma FK 506 levels for the past 3 years. 
Over the past IS months, our workload has steadily 
increased to 5,000 patient analyses per month indicating 
that at our institution this drug is used very extensively. 
During this period we have gained tremendous amount of 
experience and expertise in performing the analysis of this 
drug. 
Detailed procedures of plasma analysis of FK 506 by 
enzyme-linked immunoassay (ELISA) has been already 
published. 3 In our laboratory, use of the C-IS Sep-Pak 
column to free the drug from proteins and subsequent use 
of methanol to elute this drug from the column has been 
successfully employed. Stability studies of this drug in 
whole blood indicated that the drug is stable in blood for up 
to 4 days. This information is very important since out of 
1,600 patients who currently receive this drug, 80% are 
outpatients who send us blood specimens by overnight 
mail. 
The maximum partitioning of the drug into plasma was 
achieved by incubating the blood at 37°C for 1 hour. 
Plasma separated at 37°C normally has 30% to 40% higher 
concentrations when compared with plasma separated at 
room temperature. Modification of the original protocol 
from overnight incubation at 4°C to 2 hours incubation at 
room temperature showed a very good correlation (slope 
0.92, correlation coefficient 0.89). Use of the 2-hour incu-
bation method has enabled us to provide FK 506 results on 
the same day for critically ill patients, thus resulting in 
better patient care. 
All transplant patients develop certain infections, and as 
a result, are treated with drugs such as erythromycin, 
gentamycin, and vancomycin. Since these drugs are ad-
ministered in the presence of FK 506, their interference 
with FK 506 monoclonal antibody (MAb) was examined. 
Table 1. Summary of FK 506 AnalysiS 
Sample Analyzed 
Separation temperature 
Storage conditions 
Extraction method 
Turnaround time 
ICU patients 
All other patients . 
Plasma 
37"C 
-7O"C 
Solid phase 
8h 
24h 
Abbreviation: ICU. intensive care unit. 
-7O"C 
Solid phase 
8h 
24h 
We did not see any cross-reactivity even in the presence of 
peak concentrations of these drugs. Other immunosup-
pressants such as CyA (up to 2 /-Lg/mL) and rapamycin (up 
to 20 ng/mL) also did not show any cross-reactivity with 
the MAb. Additionally. the presence of hemoglobin (up to 
1.2 g/dL) and bilirubin (up to 25 mg/dL) did not show any 
interference in the analysis of FK 506 in plasma. Since the 
majority (75% to 80%) of this drug appears to bind to red 
blood cells, we developed a whole blood ELISA assay to 
measure FK 506 using solid phase extraction. The Whole 
blood trough FK 506 concentrations are S to 10 times 
higher in comparison with the corresponding plasma con-
centrations. 
Tables I and 2 summarize FK 506 analysis. sensitivity. 
linearity, and precision data for both plasma and whole 
blood analyses of FK 506. 
Preliminary studies in our laboratory have shown that 
high-performance liquid chromatography (HPLC) alone 
cannot be used to measure the parent drug and its metab-
olites. At the present time combination of HPLC-ELISA is 
one way to quantitate parent FK 506 in biologic fluids. We 
have recently developed an HPLC method with a gradient 
system to obtain the fractions of parent drug as well as 
possible metabolites and to further quantitate them by 
ELISA. It appears that the unchanged FK 506 is a major 
component in plasma that reacts with the MAb. Analysis 
of FK 506 by HPLC-mass spectrophotometry (HPLC-MS) 
is being currently investigated at our institution. However. 
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FK 506 ANALYSIS 
Table 2. Summary of All Parameters 
Parameter Plasma 
Sample volume 100 Ill-
Minimum detectable limit 0.1 ng/mL 
Standard curve range 0.1-10.0 ng/mL 
Control ranges ng/mL 
Level 1 1.0-2.2 
Level 2 2.3-3.7 
Level 3 4.2-6.8 
Intraday variation (n = 10) Mean' C.V.t 
Level 1 1.5 4.2 
Level 2 2.7 5.5 
Level 3 5.1 7.1 
Interday variation (n = 50) Mean' C.V.t 
Lavel1 1.4 17.0 
Level 2 2.9 14.4 
Level 3 5.7 12.0 
Abbreviation: CV. coefficient ot variation. 
'Results are in ng/mL. 
tResults are in percent. 
Blood 
25 Ill-
0.8 ng/mL 
O.!HIO.O ng/mL 
ng/mL 
8.5-12.7 
13.7-17.3 
21.4-37.1 
Mean' C.V.t 
10.6 10.0 
15.5 10.2 
29.3 13.4 
Mean' C.V.t 
9.5 14.0 
14.0 11.1 
28.0 13.0 
at the present time, in routine clinical practice. ELISA 
using solid phase extraction. is the most reliable and 
practical way to measure this drug in plasma as well as in 
whole blood. 
2731 
Future studies have to be carried out to correlate blood 
and plasma FK 506 concentrations measured by ELISA. 
HPLC-ELISA. and HPLC-MS with bioassay, immuno-
logic response measurement, and toxicity before a final 
decision is made as to the choice of the biologic fluid that 
should be used in routine clinical monitoring of FK 506. It 
is essential that in any method developed, one should 
know the nature of the compound that is being measured 
(parent drug and/or metabolites) and that the method be 
simple and provide rapid tum around time to be of practi-
cal value in treating patients. 
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